Summary
CYP2B6 inhibitors are compounds that reduce the activity of the CYP2B6 enzyme, which can reduce drug metabolism, potentially impacting the effects of drug therapy.
CYP2B6 is a cytochrome P450 (CYP) enzyme that is thought to account for just 2 to 5% of total cytochrome P450 enzymes in the liver. CYP2B6 is involved in the metabolism of any medications that are CYP2B6 substrates, as well as various pesticides and other environmental chemicals.[1] CYP2B6 inhibitors can reduce the body’s metabolism of any of these substances.
The table below outlines some of the most common or clinically relevant CYP2B6 inhibitors.[2][1][3] Importantly, this list is not exhaustive.
CYP2B6 Inhibitors |
---|
17-α-ethynylestradiol (oral contraceptives) |
Canagliflozin |
Clopidogrel |
Clotrimazole |
Sertraline |
Voriconazole |
References
- ^Zanger UM, Schwab MCytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.Pharmacol Ther.(2013-Apr)
- ^Song Y, Li C, Liu G, Liu R, Chen Y, Li W, Cao Z, Zhao B, Lu C, Liu YDrug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.Clin Pharmacokinet.(2021-May)
- ^Hakkola J, Hukkanen J, Turpeinen M, Pelkonen OInhibition and induction of CYP enzymes in humans: an update.Arch Toxicol.(2020-Nov)